Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Fulcrum Therapeutics, Inc. (FULC : NSDQ)

• Company Description    Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States. Number of Employees: 45

• Price / Volume Information    Yesterday's Closing Price: $7.94 Daily Weekly Monthly 20 Day Moving Average: 585,267 shares Shares Outstanding: 53.98 (millions) Market Capitalization: $428.60 (millions) Beta: 2.37 52 Week High: $10.13 52 Week Low: $2.32 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 24.84% 18.57% 12 Week 126.21% 97.02% Year To Date 68.94% 57.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 26 LANDSDOWNE STREET - CAMBRIDGE,MA 02139 USA ph: 617-651-8851 fax: - kgardner@lifesciadvisors.com http://www.fulcrumtx.com

• General Corporate Information    Officers Alex C. Sapir - President and Chief Executive Officer Kate Haviland - Chairman Alan Musso - Chief Financial Officer Greg Tourangeau - Vice President Sonja Banks - Director Peer Information Fulcrum Therapeutics, Inc. (CORR.) Fulcrum Therapeutics, Inc. (RSPI) Fulcrum Therapeutics, Inc. (CGXP) Fulcrum Therapeutics, Inc. (BGEN) Fulcrum Therapeutics, Inc. (GTBP) Fulcrum Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 359616109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 07/30/25 Share - Related Items Shares Outstanding: 53.98 Most Recent Split Date: (:1) Beta: 2.37 Market Capitalization: $428.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.18 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 24.66% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/30/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.88 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 34.88% vs. Previous Quarter: 9.68% Sales Growth vs. Year Ago Period: 8,990.91% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -0.20 12/31/24 - -3.94 ROA 06/30/25 - - 03/31/25 - -0.19 12/31/24 - -3.65 Current Ratio 06/30/25 - - 03/31/25 - 28.71 12/31/24 - 22.63 Quick Ratio 06/30/25 - - 03/31/25 - 28.71 12/31/24 - 22.63 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -0.64 12/31/24 - -12.16 Book Value 06/30/25 - - 03/31/25 - 4.23 12/31/24 - 4.51 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©